Llanos‐Cuentas 2014.

Study characteristics
Methods	Multicentre, double‐blind RCT Trial phase: IIb Trial design: parallel‐group, dose‐ranging trial
Participants	Number randomized: 329 Inclusion criteria: males and females aged ≥ 16 years with clinical symptoms of malaria with P vivax monoinfection with an asexual parasite density > 100/µL and < 100,000/µL of blood Exclusion criteria: receiving antimalarial treatment within 30 days of screening severe malaria, any clinically significant concurrent illness severe vomiting or a Hb < 7 g/dL pregnancy or G6PD enzyme activity < 70% of the site median
Interventions	All participants received the standard adult dose of CQ (1500 mg) over 3 days to eradicate the current infection plus: TQ 50 mg single dose (n = 55) TQ 100 mg single dose (n = 57) TQ 300 mg single dose (n = 57) TQ 600 mg single dose (n = 56) TQ/PQ matched placebo (n = 54) PQ 15 mg/day for 14 days (n = 50)
Outcomes	Outcomes included in this review: recurrence of microscopically confirmed P vivax malaria after completing treatment up to 6 months adverse events attributable to TQ Outcomes not included in this review: time to recurrence parasite clearance time fever clearance time
Notes	Location: Peru, Brazil, India and Thailand Setting: community health centres and hospitals Endemicity: endemic for vivax malaria Resistance: unknown Funding: GlaxoSmithKline, Medicines for Malaria Venture
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "A computer generated randomisation schedule, stratified by baseline parasite count."
Allocation concealment (selection bias)	Low risk	Quote: "Patients, study staff and GlaxoSmithKline personnel were masked to study treatment allocation."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Described as "Double blind, double dummy design."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Described as "Double blind, double dummy design."
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition rate in all groups < 6% of the number randomized.
Selective reporting (reporting bias)	Low risk	Absolute number of recurrences by 6 months not mentioned. However, it could be calculated from available data. The numbers were confirmed by communication with the authors.
Other bias	Low risk	None identified.